Aim: Mucositis is a frequent and debilitating inflammatory complication affecting oropharyngeal mucosa, esophagus and gastro enteric tract in oncological patients treated by radiotherapy and/ or chemotherapy. Specifically, Oral Mucositis (OM) occurs in up to 75% of patients receveing high-dose of myeloablative chemotherapy used for conditioning regimens for allogenic Hematopoietic Stem Cell Transplantation (HSCT). Clinically, OM is characterized by erythema or ulcerative lesions that can lead to several problems, including oral pain, increased risk of secondary infection due to open sores in the mucosa and difficulties in eating, drinking or speaking. In addition, narcotic analgesia and complete parenteral nutrition are commonly required after HSCT. Advantages of low-level laser therapy (LLLT) for OM are well reported in literature as a result of its anti-inflammatory, biomodulator and tissue repair properties. The absence of standardized guidelines about technical parameters (power, dose, wavelength, time of treatment) is the principal limit in the use of LLLT for OM. The aim of this pilot study is to evaluate a LLLT protocol in patients affected by OM undergoing HSCT.

The low-level laser therapy in the management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a pilot study / Rocchetti, F.; Montori, A.; Savioli, N.; Del Vecchio, A.; Palaia, G.; Tenore, Gianluca; Iori, ANNA PAOLA; Pippi, Roberto; Romeo, Umberto. - In: JOURNAL OF OSSEOINTEGRATION. - ISSN 2036-4121. - ELETTRONICO. - 9:1(2017), pp. 233-234. ((Intervento presentato al convegno XXIV Congresso Nazionale Collegio dei Docenti Universitari di Discipline Odontostomatologiche tenutosi a Milan; Italy nel 2017.

The low-level laser therapy in the management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a pilot study

Rocchetti, F.
Primo
;
Montori, A.
Secondo
;
Del Vecchio, A.;Palaia, G.;TENORE, GIANLUCA;IORI, ANNA PAOLA;PIPPI, Roberto
Penultimo
;
ROMEO, Umberto
Ultimo
2017

Abstract

Aim: Mucositis is a frequent and debilitating inflammatory complication affecting oropharyngeal mucosa, esophagus and gastro enteric tract in oncological patients treated by radiotherapy and/ or chemotherapy. Specifically, Oral Mucositis (OM) occurs in up to 75% of patients receveing high-dose of myeloablative chemotherapy used for conditioning regimens for allogenic Hematopoietic Stem Cell Transplantation (HSCT). Clinically, OM is characterized by erythema or ulcerative lesions that can lead to several problems, including oral pain, increased risk of secondary infection due to open sores in the mucosa and difficulties in eating, drinking or speaking. In addition, narcotic analgesia and complete parenteral nutrition are commonly required after HSCT. Advantages of low-level laser therapy (LLLT) for OM are well reported in literature as a result of its anti-inflammatory, biomodulator and tissue repair properties. The absence of standardized guidelines about technical parameters (power, dose, wavelength, time of treatment) is the principal limit in the use of LLLT for OM. The aim of this pilot study is to evaluate a LLLT protocol in patients affected by OM undergoing HSCT.
File allegati a questo prodotto
File Dimensione Formato  
Rocchetti_Low-level_2017.pdf

accesso aperto

Note: https://www.journalofosseointegration.eu/index.php/jo/article/view/7
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 471.98 kB
Formato Adobe PDF
471.98 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/965569
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact